Handelsavisen
prelaunch
Companies ›Healthcare ›TSTL.L
TS
TSTL.L — London Stock Exchange Medical Equipment, Supplies & Distribution

Tristel PLC

$392,00
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
3,51 %
Op margin
18,1 %
ROE
20,1 %
Net margin
14,3 %
Debt / equity
0,18
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

Tristel PLC provides infection prevention and control solutions, primarily through the sale of medical equipment and supplies to healthcare institutions.

Business. Tristel PLC (TSTL.L) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm primarily engages in the sale of medical products and supplies. It is headquartered in the United Kingdom and is listed on the London Stock Exchange. Specific details regarding operating segments or geographic revenue breakdowns are not provided.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
ActivityHealthcare Services & Equipment
Generated · model-assisted
Sell-side consensus
BUY5 analysts
4 buy1 hold0 sell
Avg 12m price target474,80

Analyst recommendations

5 analysts · consensus Buy
Buy4
Hold1
Sell0
12-month price target
474,80
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
5 analysts · indicative
Ownership
—
not yet wired
Profitability→
20,1 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning TSTL.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to TSTL.L. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Tristel PLC (TSTL.L) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm primarily engages in the sale of medical products and supplies. It is headquartered in the United Kingdom and is listed on the London Stock Exchange. Specific details regarding operating segments or geographic revenue breakdowns are not provided.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryMedical Equipment, Supplies & Distribution
    ActivityHealthcare Services & Equipment
    AI synthesis
    GENERATED

    Tristel maintains a strong liquidity position with GBP 8.644 million in cash and equivalents, and a current ratio of 3.6, indicating a robust ability to cover short-term liabilities. The company's debt-to-equity ratio is 0.18, suggesting a conservative capital structure with limited leverage. Free cash flow is GBP 0.8 million, which is modest relative to operating cash flow of GBP 10.316 million, indicating some reinvestment in operations.

    Profitability metrics show a return on equity of 20.13% and a return on assets of 14.65%, both exceeding the industry median for medical equipment and supplies firms. Gross profit of GBP 37.459 million represents 80.6% of revenue, indicating strong pricing power or cost control. Operating income of GBP 8.397 million and net income of GBP 6.64 million suggest healthy margins, though the exact cohort median comparisons are not available in the input data.

    The company's revenue is concentrated in a single business segment, with no geographic diversification disclosed in the input data. This lack of diversification may expose the company to regional economic or regulatory risks. No specific geographic revenue breakdown is provided, but the absence of multiple segments implies a single revenue stream.

    Tristel reported revenue of GBP 46.462 million in the latest period, with no prior-year data provided to assess growth. Analysts have set a mean price target of GBP 474.80, with a median of GBP 460.00, suggesting a generally positive outlook. The company's capital expenditure of GBP -1.982 million indicates some investment in operations, though the negative value may reflect a reduction in spending or a non-cash adjustment.

    Risk factors include low liquidity and dilution risk, with no immediate filing-based flags detected. The company's low debt load and strong cash position reduce credit risk, but the lack of geographic or segment diversification could increase exposure to sector-specific downturns. No dilution pressure is currently expected, and the number of shares outstanding is stable between basic and diluted shares.

    Recent events include analyst price targets and recommendations, with a mean recommendation of 1.60 (favoring buy) and three strong-buy ratings. No recent filings or transcripts are provided in the input data to detail operational or strategic developments.

    Key takeaways
    • Tristel has a strong liquidity position with a current ratio of 3.6 and GBP 8.644 million in cash and equivalents.
    • The company's return on equity of 20.13% and return on assets of 14.65% indicate strong profitability.
    • Revenue is concentrated in a single business segment, with no geographic diversification disclosed.
    • Analysts have a generally positive outlook, with a mean price target of GBP 474.80 and three strong-buy ratings.
    • The company has low debt and no immediate dilution or liquidity risks.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $392,00
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    $33.0M
    Net cashⓘ
    $2.8M
    Current ratioⓘ
    3.6
    Debt / equityⓘ
    0.2
    ROAⓘ
    14.6%
    ROEⓘ
    20.1%
    Cash conversionⓘ
    155.0%
    CapEx / revenueⓘ
    -4.3%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    0,17
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    5
    Other metrics
    Revenue
    —
    no estimate
    Segment revenue
    —
    no estimate
    Margin
    —
    no estimate
    Segment margin
    —
    no estimate
    as of 2026-05-25 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPS—no estimate—no estimate0,17
    Revenue—no estimate—no estimate51,2M GBP
    Operating income—no estimate—no estimate11,3M GBP
    Full-year consensus mean (period as reported by source) · consensus in GBP. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution5 analysts
    Strong buy3
    Buy1
    Hold1
    Sell0
    Strong sell0
    12-month price target$474,80 · Median $460,00
    Low $400,00High $560,00
    Operating income · consensus11,3M GBP
    EPS surprise
    −1,6 %
    reported vs consensus · miss
    Revenue surprise
    −9,2 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$400,00
    Mean$474,80
    Median$460,00
    High$560,00
    Spot$392,00
    +21.1 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin18,1 %Above P75
    Net Margin14,3 %Above P75
    ROE20,1 %Best in class
    Capex / Rev-4,3 %Above median
    D/E0,18Above median
    Cash Conv1,55Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Tristel PLC Market data — financials · 2026-05-29
    • Tristel PLC Market data — analyst estimates · 2026-05-29

    Ownership & reference

    Leadership

    • Matt SassoneChief Executive Officer, Executive Director
    • Paul C. SwinneyChief Executive Officer, Executive Director

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    TSTL.LCanonical
    London Stock Exchange · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-20 00:43 UTCANALYSTAnalyst coverage initiated
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage